Is Depression Genetic? What Your DNA Can Reveal

If depression runs in your family, you've probably wondered: is it in my genes, or is it just bad luck?

The short answer is both. Major depressive disorder (MDD) is approximately 30–50% heritable, meaning your DNA accounts for roughly a third to half of your vulnerability (Sullivan et al., 2000). The rest comes from life experiences - stress, trauma, relationships, and environment. But that genetic piece is real, measurable, and increasingly actionable. Understanding it won't just explain why you might be more susceptible - it can change how you treat it.

How We Know Depression Is Partly Genetic

The strongest evidence comes from twin studies. Identical twins share 100% of their DNA. If one identical twin develops depression, the other has a 40–50% chance of developing it too - far higher than the 10–25% concordance seen in fraternal twins who share only 50% of their DNA (Kendler et al., 2006).

A landmark meta-analysis of five rigorous twin studies estimated depression's heritability at 37% (95% CI: 31–42%), with the remaining variance explained by individual-specific environmental factors (Sullivan et al., 2000). Stanford's genetics program puts the number at 40–50%, with higher heritability for severe, recurrent depression (Stanford Medicine, 2023).

What this means in practice: having a first-degree relative with depression roughly doubles or triples your own risk compared to the general population (Sullivan et al., 2000).

There's No Single "Depression Gene"

Unlike conditions like sickle cell disease or cystic fibrosis, depression isn't caused by a single gene mutation. It's polygenic - influenced by hundreds or thousands of genetic variants, each contributing a tiny effect.

The largest genome-wide association study (GWAS) to date analyzed over 685,000 individuals and identified 697 independent genetic associations with major depression (Levey et al., 2025). An earlier multi-ancestry GWAS found 243 risk loci across diverse populations (Als et al., 2023). These variants cluster in genes involved in:

• Synaptic signaling - how neurons communicate
• Neuronal development - how the brain wires itself
• Immune and inflammatory pathways - chronic inflammation's link to mood
• Hormone regulation - stress response via the HPA axis

Each individual variant nudges your risk by a fraction of a percent. It's the cumulative weight of hundreds of these variants - captured by a polygenic risk score (PRS) - that meaningfully predicts susceptibility. Current PRS models explain approximately 1.5–3% of the variance in depression risk, which sounds small but is growing rapidly as study sizes increase (Howard et al., 2019). To learn more about how polygenic scores work, see our guide to polygenic risk scores.

Key Genes Linked to Depression

While no single gene causes depression, several have strong research backing:

SLC6A4 - The Serotonin Transporter Gene

This gene encodes the serotonin transporter protein, which recycles serotonin from the synapse back into the neuron. A well-studied polymorphism called 5-HTTLPR has a "short" allele that reduces serotonin transporter expression. The landmark Caspi et al. (2003) study found that individuals with one or two short alleles were up to twice as likely to develop depression after stressful life events - a classic example of gene–environment interaction.

The 5-HTTLPR finding has been debated. A large 2019 meta-analysis questioned its direct association with depression (Border et al., 2019). However, more recent work confirms that SLC6A4 variants do interact with HTR1A (serotonin receptor) variants to influence antidepressant response, making this gene clinically relevant for pharmacogenomics (Nature, 2025).

BDNF - Brain-Derived Neurotrophic Factor

BDNF supports neuron growth and survival. The Val66Met polymorphism (rs6265) reduces activity-dependent secretion of BDNF protein. Carriers of the Met allele show reduced hippocampal volume and impaired stress resilience in some studies (Egan et al., 2003). About 20–30% of people of European ancestry carry at least one Met allele.

FKBP5 - The Stress Response Gene

FKBP5 regulates the glucocorticoid receptor, a key player in the body's stress response (HPA axis). Specific variants in FKBP5 interact with childhood trauma to dramatically increase depression risk through epigenetic mechanisms - the gene's methylation pattern literally changes in response to early-life stress (Klengel et al., 2013).

CYP2D6 and CYP2C19 - Drug Metabolism Genes

These aren't depression risk genes per se, but they determine how your body processes antidepressants. About 7% of people are poor metabolizers of CYP2D6, meaning standard doses of SSRIs or tricyclics can build up to toxic levels. Another 5–10% are ultrarapid metabolizers, burning through medication before it works (Hicks et al., 2015). We cover this in depth in our pharmacogenomics guide and our article on DNA testing for antidepressants.

Gene–Environment Interaction: Why Genes Aren't Destiny

Having a high genetic risk for depression doesn't mean you'll develop it. The field of gene–environment interaction (G×E) shows that genes and life experiences don't just add up - they multiply each other's effects.

The best-documented example: individuals with certain SLC6A4 and FKBP5 variants who experience childhood maltreatment have dramatically higher depression rates than people with the same genes but no trauma - or the same trauma but different genes (Caspi et al., 2003; Klengel et al., 2013).

Epigenetics provides the mechanism. Stressful experiences can add chemical tags (methyl groups) to DNA, silencing or activating genes without changing the DNA sequence itself. These epigenetic marks can persist for years and, in some cases, may even be passed to offspring (Nestler et al., 2016). This is why two people with identical depression polygenic risk scores can have completely different outcomes - their environments shape how those genes express themselves.

What You Can Actually Do With This Information

1. Get Pharmacogenomic Testing

If you're starting or struggling with antidepressants, knowing your CYP2D6, CYP2C19, and CYP2C9 genotypes can help your doctor choose the right medication and dose. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for tricyclic antidepressants and SSRIs based on these genes (Hicks et al., 2015). Upload your raw DNA data to GenomeInsight to check your drug metabolism genes.

2. Understand Your Risk - Don't Fear It

A higher genetic risk means increased vigilance, not inevitability. If depression runs in your family, prioritize evidence-based protective factors: regular exercise (which increases BDNF), strong social connections, adequate sleep, and stress management (Schuch et al., 2016).

3. Talk to Your Doctor With Data

Bringing your genetic data to a clinical conversation isn't overstepping - it's being an informed patient. A VA study found that patients whose physicians used pharmacogenomic testing had significantly better depression remission rates than those on standard treatment (Oslin et al., 2022).

4. Explore Your Full Genetic Profile

Depression risk genes don't exist in isolation. They overlap with genes for anxiety, bipolar disorder, ADHD, and substance use. A comprehensive DNA health report can reveal how your genetic variants interact across multiple conditions.

Key Takeaways

• Depression is 30–50% heritable - genes are a real and significant risk factor, but not the whole story
• There's no single depression gene; hundreds of variants contribute small effects that add up
• Gene–environment interactions mean your life experiences shape how depression genes express themselves
• Pharmacogenomic testing (CYP2D6, CYP2C19) can directly improve antidepressant treatment outcomes
• Knowing your genetic risk empowers prevention, not fatalism - exercise, sleep, and social connection are evidence-based buffers
• Upload your DNA data to GenomeInsight to explore your mental health-related variants and drug metabolism profile

References

Als, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therber, K., Lam, M., ... & Børglum, A. D. (2023). Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. Nature Medicine, 29(7), 1832–1844.

Border, R., Johnson, E. C., Evans, L. M., Smolen, A., Berley, N., Sullivan, P. F., & Keller, M. C. (2019). No support for historical candidate gene or candidate gene-by-interaction hypotheses for major depression across multiple large samples. American Journal of Psychiatry, 176(5), 376–387.

Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., ... & Poulton, R. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386–389.

Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., ... & Weinberger, D. R. (2003). The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell, 112(2), 257–269.

Hicks, J. K., Bishop, J. R., Sangkuhl, K., Müller, D. J., Ji, Y., Leckband, S. G., ... & Altman, R. B. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clinical Pharmacology & Therapeutics, 98(2), 127–134.

Howard, D. M., Adams, M. J., Clarke, T. K., Hafferty, J. D., Gibson, J., Shirali, M., ... & McIntosh, A. M. (2019). Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 22(3), 343–352.

Kendler, K. S., Gatz, M., Gardner, C. O., & Pedersen, N. L. (2006). A Swedish national twin study of lifetime major depression. American Journal of Psychiatry, 163(1), 109–114.

Klengel, T., Mehta, D., Anacker, C., Rex-Haffner, M., Pruessner, J. C., Pariante, C. M., ... & Binder, E. B. (2013). Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interaction. Nature Neuroscience, 16(1), 33–41.

Levey, D. F., Stein, M. B., Wendt, F. R., Pathak, G. A., Zhou, H., Aslan, M., ... & Gelernter, J. (2025). Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell, 188(3), 624–639.

Nestler, E. J., Peña, C. J., Kundakovic, M., Mitchell, A., & Akbarian, S. (2016). Epigenetic basis of mental illness. The Neuroscientist, 22(5), 447–463.

Oslin, D. W., Lynch, K. G., Shih, M. C., Ingram, E. P., Wray, L. O., Chapman, S. R., ... & Thase, M. E. (2022). Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder. JAMA, 328(2), 151–161.

Schuch, F. B., Vancampfort, D., Richards, J., Rosenbaum, S., Ward, P. B., & Stubbs, B. (2016). Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research, 77, 42–51.

Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000). Genetic epidemiology of major depression: Review and meta-analysis. American Journal of Psychiatry, 157(10), 1552–1562.

---

Related Reading

• anxiety and PTSD genetics